Bartolomeo Bosco

Humboldt-Universität zu Berlin — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

7h-index183citations24works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(14), Lung Cancer Treatments and Mutations(13), Cancer Research and Treatments(6), Cancer-related Molecular Pathways(5), Pancreatic and Hepatic Oncology Research(4)

Publications24 total

Table S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Figure S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Figure S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Figure S5 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Figure S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Figure S6 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Data from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Figure S8 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Figure S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Figure S7 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Table S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Table S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Table S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i>-Amplified Cancers
2025Open Access
Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in <i>MYCN</i> -Amplified Cancers
Cancer Discovery·2025· 4 citedOpen Access
CLK2 and CLK4 are regulators of DNA damage-induced NF-κB targeted by novel small molecule inhibitors
Cell chemical biology·2023· 11 citedOpen Access
DHX30 Coordinates Cytoplasmic Translation and Mitochondrial Function Contributing to Cancer Cell Survival
Cancers·2021· 20 citedOpen Access
A selective p53 activator and anticancer agent to improve colorectal cancer therapy
Cell Reports·2021· 35 citedOpen Access
DHX30 coordinates cytoplasmic translation and mitochondrial function contributing to cancer cell survival
2020· 1 citedOpen Access
SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma
Cancers·2019· 29 citedOpen Access
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Journal of Visualized Experiments·2019· 3 cited
page 1 of 2Next →

Frequent Co-authors

Giulia Montuori(14), Fengyu Tu(14), Di Qin(14), Rachel Schmargon(14), Elias Rodríguez-Fos(14), Konstantin Helmsauer(14), Hui Hui(14), Susmita Mandal(14), Karin Purshouse(14), Lara Fankhänel(14), Bastiaan Spanjaard(14), Hannah Seyboldt(14), Laura Grunewald(14), Matthias Jürgen Schmitt(14), Dennis Gürgen(14), Viktoria Buck(14), Mathias T. Rosenfeldt(14), Frank Dubois(14), Simon Schallenberg(14), Annika Lehmann(14)